Melanoma Relapse: New Hope with Immunotherapy and Surgery
For patients facing locoregional relapse of melanoma after initial treatment, a new strategy combining immunotherapy with nivolumab and ipilimumab, followed by surgical resection, is showing promising results. Presented at the ESMO Sarcoma and Rare Cancers Congress 2026, a recent study offers a potential path forward in a clinical setting where treatment options have historically been limited.
The Challenge of Melanoma Relapse
Melanoma, a serious form of skin cancer, has seen significant advances in treatment with immune checkpoint inhibitors and targeted therapies. However, what happens when the cancer returns locally after initial adjuvant therapy? This is a critical question, as standard approaches haven’t always provided definitive answers. Understanding the best way to manage these relapses is crucial for improving patient outcomes.
Study Details: A Retrospective Analysis
Researchers conducted a single-center, retrospective study focusing on 12 patients with stage III melanoma who had experienced locoregional relapse after completing adjuvant therapy. All patients received induction immunotherapy with nivolumab plus ipilimumab before undergoing curative-intent surgery. The study analyzed baseline characteristics, treatment outcomes, and pathological responses.
Key Findings: Encouraging Results
The results revealed a significant benefit from this combined approach. At three years after starting immunotherapy, the progression-free survival rate was 55%, and the overall survival rate reached 92%. Notably, four patients achieved a complete or major pathological response. Interestingly, the study found no correlation between how the tumor appeared to respond on radiological scans (RECIST 1.1) and the actual pathological response observed during surgery.
The study too indicated that outcomes were consistent regardless of BRAF mutation status, a common genetic factor in melanoma. Importantly, patients who achieved a major pathological response did not experience relapse or death during the follow-up period.
Why This Matters: The Role of Multidisciplinary Care
These findings suggest that combining nivolumab and ipilimumab followed by surgery can be an effective salvage strategy for patients with locoregional melanoma relapse. The lack of correlation between radiological and pathological response underscores the importance of a multidisciplinary approach, involving careful surgical evaluation even when imaging isn’t conclusive.
Did you know? Nivolumab is an anti-PD-1 drug, while ipilimumab is an anti-CTLA-4 drug. Both work by boosting the body’s immune system to fight cancer cells. [4]
Future Trends and Implications
The success of this approach highlights a growing trend in melanoma treatment: personalized strategies that combine different modalities. The combination of immunotherapy and surgery is likely to become more common, particularly in cases of locoregional relapse. Further research is needed to identify biomarkers that can predict which patients are most likely to benefit from this approach.
Recent long-term data from the CheckMate 067 trial demonstrate the sustained benefit of nivolumab plus ipilimumab in advanced melanoma, with a hazard ratio for death of 0.53 compared to ipilimumab alone. [1, 2] This reinforces the potential of this combination in various stages of the disease.
The PRADO cohort of the OpACIN-neo trial showed impressive 5-year survival rates with neoadjuvant ipilimumab plus nivolumab in stage III melanoma, with 86% overall survival. [3] This suggests that early intervention with immunotherapy can significantly improve long-term outcomes.
FAQ
Q: What is locoregional relapse?
A: Locoregional relapse means the cancer has returned in the area where it was originally treated, or in nearby lymph nodes.
Q: What are nivolumab and ipilimumab?
A: These are immunotherapy drugs that help your immune system fight cancer. [4]
Q: Is surgery still key if immunotherapy is working?
A: Yes, the study showed that surgery can be crucial, even if imaging doesn’t show a strong response.
Q: Does BRAF mutation status affect the outcome?
A: This study found that outcomes were similar regardless of BRAF mutation status.
Pro Tip: If you’ve been diagnosed with melanoma, discuss all treatment options with your oncologist and consider seeking a second opinion.
Learn more about the study by reading the full abstract.
Want to stay informed about the latest melanoma research? Subscribe to our newsletter for updates, and insights.
